Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Myung Ju Ahn 7 Articles
Modest Anti-Cancer Activity of a Bile Acid Acylated Heparin Derivative in a PC14PE6 Induced Orthotopic Lung Cancer Model
Zheng Yun Cui, Min Jae Park, Jeeyun Lee, Jin Seok Ahn, Myung Ju Ahn, Soo Won Seo, Jin Woo Park, Youngro Byun, Keunchil Park
Cancer Res Treat. 2009;41(2):80-86.   Published online June 30, 2009
DOI: https://doi.org/10.4143/crt.2009.41.2.80
AbstractAbstract PDFPubReaderePub
Purpose

A novel chemically modified heparin derivative, heparin-deoxycholic acid nano-particles, has lower anticoagulant activity, and was recently reported to have significant anti-tumor effects on squamous head and neck cancer cells. Therefore, the aim of this study was to evaluate the anti-tumor effects of heparin-deoxycholic acid nano-particles in a human lung adenocarcinoma cell line.

Materials and Methods

An orthotopic lung cancer model in 16 mice was developed using intra-thoracic injections of 0.5×106 PC14PE6 cells. Ten days after inoculation, the mice were divided into two groups. PBS and Heparin-DOCA particles were injected once a day every 3 days in the tail vein, for a total of 5 injections. The body weight and survival of each mouse were monitored and the tumor size in the lung was measured by SPECT-CT before and after heparin-DOCA nano-particle treatment.

Results

IThe HD particles had no significant cytotoxicity when the PC9 cells were treated in vitro. There was no statistical difference in tumor size, body weight and survival between the HD treated and control groups in vivo. Furthermore, there was no difference in the amount of CD31 between tumor tissues in the two study groups.

Conclusion

HD synthesized with unfractionated heparin had no apparent inhibitory effects on tumor growth in a PC14PE6 cell induced orthotopic lung cancer mouse model. The HD particles did not significantly inhibit tumor-induced angiogenesis at the tumor sites.

Citations

Citations to this article as recorded by  
  • Improvement of orthotopic lung cancer mouse model via thoracotomy and orotracheal intubation enabling in vivo imaging studies
    Geun Ho Im, Moon-Sun Jang, Julius Juhyun Chung, Kyoung-Nam Kim, Jae-Hun Kim, Sun I Kim, Jung Hee Lee
    Laboratory Animals.2014; 48(2): 124.     CrossRef
  • The antiangiogenic properties of sulfated β-cyclodextrins in anticancer formulations incorporating 5-fluorouracil
    Clare A. Watson, Kara L. Vine, Julie M. Locke, Anna Bezos, Christopher R. Parish, Marie Ranson
    Anti-Cancer Drugs.2013; 24(7): 704.     CrossRef
  • 9,528 View
  • 47 Download
  • 2 Crossref
Close layer
Proteomic Profiling of Human Small Cell Lung Cancer Cell Line NCI-H211
Hee Young Cho, Mi Kyung Kim, Young Do Yoo, Myung Ju Ahn, Joung Soon Jang
Cancer Res Treat. 2003;35(6):489-496.   Published online December 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.6.489
AbstractAbstract PDF
PURPOSE
Small cell lung cancer is one of the major causes of death from cancer worldwide. To explore the expressions of global protein in small cell lung cancer cells, a proteomic approach, to identify the proteins, was used and the establishment of a protein reference map attempted.
MATERIALS AND METHODS
Two-dimensional gel electrophoresis (2-DE), with subsequent analysis by mass spectrometry (MS), was applied to the study of protein identification from a small cell lung cancer cell line, NCI- H211. The cells were lysed, and the extracts subjected to isoelectric focusing, with immobilized pH gradients, followed by second dimension SDS-PAGE. The polypeptides were identified by peptide mass fingerprinting, with MALDI-TOF MS, after in-gel protein digestion. RESULTS: From silver staining of the gel, around two thousands protein spots were separated by the 2-DE. Of these protein spots visualized in the gel, one hundred and ten were identified by peptide mass fingerprinting. Different proteins, such as enzymes, cytoskeletal proteins and proteins common to eukaryotic cells, were identified.
CONCLUSION
The protein expressions of the small cell lung cancer cells were analyzed to establish a protein reference map. The reference map presented here may serve as a working tool for the further study of small cell lung cancer.
  • 4,123 View
  • 49 Download
Close layer
Combination Chemotherapy of Oxaliplatin and Capecitabine in Patients with Metastatic Colorectal Cancer: a Pilot Study
Myung Ju Ahn, Ho Suck Oh, Jung Hye Choi, Young Yeul Lee, In Soon Kim, Il Young Choi, Oh Young Lee, Heung Woo Lee
Cancer Res Treat. 2003;35(5):407-410.   Published online October 31, 2003
DOI: https://doi.org/10.4143/crt.2003.35.5.407
AbstractAbstract PDF
PURPOSE
To evaluate the efficacy and toxicity of oxaliplatin and capecitabine in patients with metastatic colorectal cancer. MATERIALS AND METHODS: Between December 2001 and April 2003, fourteen patients were enrolled in this study. Oxaliplatin, 80 mg/m(2), was administered intravenously on day 1, and capecitabine, 1, 250 mg/m(2) bid po (total daily dose 2, 500 mg/m(2)), was given on days 1~14 of 3 week cycles. RESULTS: The median age of the patients was 57 years (range: 41~74), and the most common sites of metastasis were liver, lung or lymph node. Of the 12 evaluable patients, the overall response rate was 41.7%, but with no complete response. The median response duration and median progression free survival of 12 patients were 42 and 24.4 weeks, respectively. The median overall survival was not reached. A median 6 (range: 1~9), and a total 80, cycles were administered to 14 patients. 80 cycles were evaluable for toxicity. The most common hematological toxicities were NCI grades I/II anemia (45%), leucopenia (33.75%) and thrombocytopenia (17.5%). The most common non-hematological toxicities were nausea/ vomiting (28.75/5%) and neurotoxicity (8.75%). Hand and foot syndrome was noted in only 3.75%. There was no life-threatening toxicity.
CONCLUSION
Oxaliplatin and oral capecitabine combination chemotherapy showed significant activity and favorable toxicity in patients with metastatic colorectal cancer. Further studies, with larger numbers of patients and long-tern follow-up will be needed.

Citations

Citations to this article as recorded by  
  • Case Report: Vision Loss Induced by Capecitabine in Patient with Preexisting Left Eyes Blind
    Paul Matte, Michel Ducreux
    Case Reports in Oncology.2023; : 480.     CrossRef
  • Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    J H Baek, J G Kim, S B Jeon, Y S Chae, D H Kim, S K Sohn, K B Lee, Y J Choi, H J Shin, J S Chung, G J Cho, H Y Jung, W Yu
    British Journal of Cancer.2006; 94(10): 1407.     CrossRef
  • 4,655 View
  • 21 Download
  • 2 Crossref
Close layer
Gemcitabine and Infusional 5-Fluorouracil in Advanced Pancreatic Cancer: A Clinical Benefit Response-Oriented Phase II Study
Jung Hye Choi, Myung Ju Ahn, Seock Ah Im, Bong Seog Kim, Ho Suk Oh, Heung Woo Lee, Yeung Chul Mun, Chu Myung Seong, Soon Nam Lee, Young Yeul Lee, Il Young Choi, In Soon Kim
Cancer Res Treat. 2003;35(3):213-217.   Published online June 30, 2003
DOI: https://doi.org/10.4143/crt.2003.35.3.213
AbstractAbstract PDF
PURPOSE
Gemcitabine and 5-fluorouracil (5-FU) are two compounds with reproducible activity against advanced pancreatic carcinomas. To evaluate the activity and feasibility of this combination chemotherapy, a multi-institutional phase II study was performed. MATERIALS AND METHODS: Twenty patients (male: female 15: 5, median age: 60.5 years), with histologically verified locally advanced or metastatic pancreatic carcinomas, were enrolled between April 2000 and March 2002. Gemcitabine was administered by intravenous injection at the doses of 1, 000 mg/m2 on days 1, 8 and 15, and 5-FU 800 mg/m2/day, was given by continuous intravenous infusion on days 1~5. The treatment was repeated every 4 weeks. The clinical benefit response (CBR) was a composite of the pain, Karnofsky performance status and body weight change measurement.
RESULTS
Nineteen of the twenty patients were assessable for response. The median follow-up duration was 4.6 months (0.4~15.2 months). Five patients achieved a partial response and eight a stable disease. The overall response rate was 25.0%. The CBR was assessable in 12 patients. The overall CBR was 41.7% (5/12). The median survival of all the patients was 8.0 months. Grade 3~4 toxicities included neutropenia (9.3%) and thrombocytopenia (5.3%). CONCLUSION: This study suggested that gemcitabine, combined with infusional 5-FU, was well tolerated, and produced modest antitumor activity and symptomatic relief in advanced pancreatic cancer patients.
  • 3,720 View
  • 32 Download
Close layer
Randomized Controlled Open Labelled, Phase III Trials, Comparing the Efficacy between Fentas(R) and Durogesic(R) Patches in Controlling Cancer Pain: Multicenter Trial
Myung Ju Ahn, Tae June Jung, Jung Hye Choi, Mi Ran Oh, Hwi Joong Yoon, Jun Suk Kim, Chul Won Choi, Kyung Wook Hur, Dae Sik Hong, Hee Sook Park, Sung Kyu Park, Jung Ae Lee, Young Suk Park, Hyonggi Jung
Cancer Res Treat. 2002;34(3):165-169.   Published online June 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.3.165
AbstractAbstract PDF
PURPOSE
Fentanyl is a synthetic opioid and transdermal therapeutic system (TTS), designed to release the drug into the skin at a constant rate, ranging from 25 to 100 microgram/hr, for up to 3 days. For the control of chronic cancer pain, Durogesic(R) patches (Janssen Co., USA) are now widely used. Recently, the Hana Company in Korea developed a new fentanyl patch, Fentas(R) using a different method. To compare the efficacy, and safety, of the fentanyl patch manufactured in Korea (Hana Pharm. Co. Ltd), with the Durogesic(R) patch, in controlling cancer pain, we performed randomized controlled, open labelled, phase III studies. MATERIALS AND METGODS: From January 2000 to April 2001, 85 patients were enrolled, 69 of whom (42 in D arm and 43 in F arm) completed the study, and were therefore assessable for per protocol (PP) analyses.
RESULTS
There were no significant differences between the two groups in baseline characteristics, with the exception of age. The primary end point was to show the therapeutic equivalence of the two patches. In these clinical trials, the confidence interval of difference, between the test drug (Fentas(R)) and the control (Durogesic(R)), was 0.027~ +0.124 by intention to treat (ITT) analysis. Even if the upper confidence interval exceeds + 0.1, the test drug is not superior to the control drug, because the confidence interval includes 0. However, by PP analysis, the confidence interval lies exactly within +/- 0.1. Therefore, we could conclude the two patches are therapeutically equivalent. The second endpoint was the difference of visual analog scale (VAS) between the baseline and the average of three measurements after treatment. The difference in VAS was 50.44+/-10.28 for the F arm, and 44.69+/-11.00 for the D arm. By PP analysis the test drug was superior to the control (p=0.028). The rescue morphine amount was 81.21+/-124.76 for F arm and 66.19+/-115.9 for D arm, and there was no significant difference between the two groups (p=0.6063). The most common adverse effects of both fentanyl patches were nausea or vomiting (55.3%), somnolence (50.0%), constipation (39.5%), gastrointestinal discomfort (57.9%) and headaches (25.0%). In general there was no significant difference in side effects or laboratory data between the two groups.
CONCLUSION
These findings suggest that Fentas(R) patches, administered every 3 days, are effective, safe, and well tolerated for the treatment of most patients with cancer pain and is as effective or better than Durogesic(R).
  • 4,363 View
  • 32 Download
Close layer
Clinical Prognostic Factors and Treatment Outcome of Aggressive Non-Hodgkin's Lymphoma in Elderly Patients
Jung Hye Choi, Myung Ju Ahn, Mo Ran Ki, Ho Suk Oh, Young Yuel Lee, Il Young Choi, In Soon Kim
Cancer Res Treat. 2001;33(4):324-328.   Published online August 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.4.324
AbstractAbstract PDF
PURPOSE
The aim of this study was to determine the prognostic factors and treatment outcome of for elderly patients (age>or=60 at time of diagnosis) with aggressive non-Hodgkin's lymphoma (NHL).
MATERIALS AND METHODS
We analyzed 52 patients diagnosed with aggressive NHL between January 1990 and May 2000.
RESULTS
The patient's median age was 69 years (range: 60~92). Thirty-two (61.5%) patients were male. Patients included those with diffuse large B cell (53.8%), peripheral T cell (23.1%), AILD-like T-cell (3.8%), angiocentric (3.8%), mantle cell (3.8%), Burkitt's lymphoma (3.8%), and others (7.9%). International prognostic index (IPI) parameters were as follows: elevated LDH (60.8%), ECOG performance status>or=2 (32.7%), advanced stage (III/IV, 62.7%), and extranodal site>or=2 (11.5%). Twenty-six (50.0%) patients demonstrated a high and high-intermediate IPI. The median follow-up for surviving patients was 26.6 months. The overall median survival was 22.7 months and the 2-year survival rate was 46.9%. Among the 49 patientstreated with chemotherapy, 28 (57.1%) patients achieved complete remission (CR). Univariate analysis identified 8 prognostic factors for overall survival: age<70 (P=0.04), low/low-intermediate IPI (P=0.02), good performance (P= 0.04), normal WBC (P=0.008), normal Hb (P=0.02), normal LDH (P=0.04), CR on first line therapy (P<0.001), and absence of B symptom (P=0.001). In the multivariate analysis, the independent prognostic factors for improved overall survival were age <70 (P=0.03), low/low-intermediate IPI (P=0.03), normal WBC (P=0.006), and CR on first line therapy (P<0.001).
CONCLUSION
In our experience, even elderly patients (>or=60 years) with aggressive NHL can be successfully treated with conventional chemotherapy and the important prognostic factors for survival are age, IPI, initial WBC, and CR on first line treatment.

Citations

Citations to this article as recorded by  
  • Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
    Jee Hyun Kim, Do-Youn Oh, Yu Jung Kim, Sae Won Han, In-Sil Choi, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Jong-Seok Lee, Dae-Seog Heo, Yung-Jue Bang, Noe Kyeong Kim
    Journal of Korean Medical Science.2005; 20(5): 806.     CrossRef
  • Doxorubicin‐based chemotherapy for diffuse large B‐cell lymphoma in elderly patients
    Keun‐Wook Lee, Dae‐Young Kim, Tak Yun, Dong‐Wan Kim, Tae‐You Kim, Sung‐Soo Yoon, Dae Seog Heo, Yung‐Jue Bang, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim
    Cancer.2003; 98(12): 2651.     CrossRef
  • 3,905 View
  • 24 Download
  • 2 Crossref
Close layer
Grnulocyte Colony - Stimulating Factor , Filgrastim ( G - CSF , Filgastrim ) in Acute Leukemia after Remission Induction Chemotherapy
Cheol Won Suh, Sung Bae Kim, Sang Hee Kim, Young Ran Chae, Byoug Soon Doh, Sang We Kim, Myung Ju Ahn, Kyoo Hyung Lee, Jung Shin Lee
J Korean Cancer Assoc. 1994;26(3):431-438.
AbstractAbstract PDF
Objectives
Colony stimulating factors have been shown to accelerate recovery from severe neutropenia after intensive chemotherapy. To prove its clinical effectiveness, we conducted controlled study to administer G-CSF in acute leukemia after induction chemotherapy. Methods: Forty patients with newly diagnosed and relapsed or refractory acute leukemia after remission induction chemotherapy were randomly assigned to one of two groupa (20 G- CSF treated group, 20 control grouP). Treatment with G-CSF(200 ug/m(2)/d) was started 48 hours after the end of chemotherapy and continued until the neutrophil count rose above 1,500 /mm(3). Results: Treatment with G-CSF shortened neutropenic period after chemotherapy, i.e., median duration of neutrophil counts less than 1,000/mm(3) was 21 days in control group and 12 days in G-CSF treated group. The incidence of infection was 80%in control group, 70% in G-CSF treated group, but it did not show any statistically significant difference. Microbiologically documented infection was 40% in control group, 20% in G-CSF treated group. Febrile periods and duration of antibiotic administration were decreased to 7 days and 18 days respectively. In G- CSF treated group, two Patients reported mild bone pain. There was no evidence that G-CSF could increase remission duratian and survival. Conclusion: It appears that recombinant G-CSF is safe and useful in neutropenic patients after intensive chemotherapy, accelerating neutrophil recovery and thereby reducing the incidence of documented infection and duration of antibiotic ad#ministration.
  • 3,043 View
  • 18 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP